This is an old revision of this page, as edited by Bon courage (talk | contribs) at 16:26, 9 April 2021 (→Selected publications: selected by whom; Misplaced Pages is not a miscellaneous bibliographic assembly service). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 16:26, 9 April 2021 by Bon courage (talk | contribs) (→Selected publications: selected by whom; Misplaced Pages is not a miscellaneous bibliographic assembly service)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)| Edward Tobinick | |
|---|---|
| Born | New York City, US |
| Nationality | American |
| Alma mater | Brandeis University (B.S. Biology, 1973) UC San Diego School of Medicine (M.D., 1977) |
| Occupation | Physician |
| Known for | Perispinal Etanercept |
| Website | http://www.nrimed.com |
Edward Tobinick M.D. is an American physician, inventor, and scientist, who invented the use of the drug etanercept for chronic neurological dysfunction after stroke and brain injury, with multiple issued U.S. and foreign patents, including U.S. patent 8,900,583.
References
- Singh, Anita (February 7, 2017). "Andrew Marr: how having a stroke changed my marriage for the better". The Telegraph. Retrieved November 17, 2018.
- "New hope for survivors of stroke and traumatic brain injury". Springer Select. October 31, 2012. Retrieved November 17, 2018.
Selected patents
| Year Issued | Inventor | Title | Country |
|---|---|---|---|
| 2009 | Edward Tobinick | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers. U.S. Patent 7,629,311” | US |
| 2014 | Edward Tobinick | Methods for treatment of brain injury using biologics. U.S. Patent 8,900,583 | US |